Literature DB >> 25234629

[Clinical features and therapy of rheumatic diseases and vasculitides in childhood].

K Tenbrock1.   

Abstract

Rheumatic diseases are the second most common autoimmune disease in childhood after diabetes mellitus. Because cutaneous findings are so common, a dermatologist is often the first physician these children and their parents see. The most common rheumatic disease is juvenile idiopathic arthritis. Except for the systemic form and psoriatic arthritis JIA usually does not show cutaneous symptoms. However, there are many rheumatic diseases that start with skin manifestations such as Henoch-Schönlein purpura, systemic lupus erythematosus and Kawasaki syndrome. Knowledge of these diseases and their symptoms is therefore of importance for the dermatologist.

Entities:  

Mesh:

Year:  2014        PMID: 25234629     DOI: 10.1007/s00105-014-2847-7

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  27 in total

1.  Methotrexate and corticosteroid therapy for pediatric localized scleroderma.

Authors:  Y Uziel; B M Feldman; B R Krafchik; R S Yeung; R M Laxer
Journal:  J Pediatr       Date:  2000-01       Impact factor: 4.406

2.  Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study.

Authors:  F Zulian; B H Athreya; R Laxer; A M Nelson; S K Feitosa de Oliveira; M G Punaro; R Cuttica; G C Higgins; L W A Van Suijlekom-Smit; T L Moore; C Lindsley; J Garcia-Consuegra; M O Esteves Hilário; L Lepore; C A Silva; C Machado; S M Garay; Y Uziel; G Martini; I Foeldvari; A Peserico; P Woo; J Harper
Journal:  Rheumatology (Oxford)       Date:  2005-12-20       Impact factor: 7.580

3.  Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.

Authors:  Philip J Mease; Dafna D Gladman; Christopher T Ritchlin; Eric M Ruderman; Serge D Steinfeld; Ernest H S Choy; John T Sharp; Peter A Ory; Renee J Perdok; Mark A Weinberg
Journal:  Arthritis Rheum       Date:  2005-10

4.  The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.

Authors:  M S Heiberg; C Kaufmann; E Rødevand; K Mikkelsen; W Koldingsnes; P Mowinckel; T K Kvien
Journal:  Ann Rheum Dis       Date:  2007-01-09       Impact factor: 19.103

5.  Randomized, placebo-controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis.

Authors:  P Woo; T R Southwood; A M Prieur; C J Doré; J Grainger; J David; C Ryder; N Hasson; A Hall; I Lemelle
Journal:  Arthritis Rheum       Date:  2000-08

6.  Construct validity of ILAR and EULAR criteria in juvenile idiopathic arthritis: a population based incidence study from the Nordic countries. International League of Associations for Rheumatology. European League Against Rheumatism.

Authors:  L Berntson; A Fasth; B Andersson-Gäre; J Kristinsson; P Lahdenne; G Marhaug; S Nielsen; P Pelkonen; E Svensson
Journal:  J Rheumatol       Date:  2001-12       Impact factor: 4.666

Review 7.  Clinical practice: Diagnosis and management of Henoch-Schönlein purpura.

Authors:  Hugh J McCarthy; E Jane Tizard
Journal:  Eur J Pediatr       Date:  2009-12-12       Impact factor: 3.183

8.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.

Authors:  Nicolino Ruperto; Daniel J Lovell; Pierre Quartier; Eliana Paz; Nadina Rubio-Pérez; Clovis A Silva; Carlos Abud-Mendoza; Ruben Burgos-Vargas; Valeria Gerloni; Jose A Melo-Gomes; Claudia Saad-Magalhães; Flavio Sztajnbok; Claudia Goldenstein-Schainberg; Morton Scheinberg; Immaculada Calvo Penades; Michael Fischbach; Javier Orozco; Philip J Hashkes; Christine Hom; Lawrence Jung; Loredana Lepore; Sheila Oliveira; Carol A Wallace; Leonard H Sigal; Alan J Block; Allison Covucci; Alberto Martini; Edward H Giannini
Journal:  Lancet       Date:  2008-07-14       Impact factor: 79.321

9.  Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

Authors:  Daniel J Lovell; Nicolino Ruperto; Steven Goodman; Andreas Reiff; Lawrence Jung; Katerina Jarosova; Dana Nemcova; Richard Mouy; Christy Sandborg; John Bohnsack; Dirk Elewaut; Ivan Foeldvari; Valeria Gerloni; Jozef Rovensky; Kirsten Minden; Richard K Vehe; L Wagner Weiner; Gerd Horneff; Hans-Iko Huppertz; Nancy Y Olson; John R Medich; Roberto Carcereri-De-Prati; Melissa J McIlraith; Edward H Giannini; Alberto Martini
Journal:  N Engl J Med       Date:  2008-08-21       Impact factor: 91.245

10.  Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis.

Authors:  Kelly A Rouster-Stevens; Aneel Gursahaney; Ka-Leung Ngai; Jennifer A Daru; Lauren M Pachman
Journal:  Arthritis Rheum       Date:  2008-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.